References
- Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1–24
- Rubin LG. Pneumococcal vaccine. Pediatr Clin North Am 2000;47(2): 269–85
- Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9): 1–35
- Barry AL. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. Am J Med 1999; 107(1A):28–33S
- Kaplan SL, Mason EO Jr, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 1998;102(3 Pt 1):538–45
- Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269(2): 221–6
- Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984;149(6): 861–9
- Douglas RM, Paton JC, Duncan SJ, et al. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148(1): 131–7
- Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171(4): 885–9
- Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococcal during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174(6): 1271–8
- Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999;180(4): 1171–6
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis 2000; 19(3): 187–95
- Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR CDC Surveill Summ 2002; 51(RR-2): 1–36
- Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344(6): 403–9
- Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;314(25): 1593–9
- Dagan R, Givon N, Yagupsky P, et al. Effect of a 9-valent pneumococcal vaccine conjugated to CRM 197 (PncCRM9) on nasopharyngeal carriage of vaccine type and non-vaccine type S pneumoniae strains among day care center attendees. (Abstr G-52) Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Sept 24–27, 1998. Washington, DC: American Society of Microbiology, 1998: 299
- Miller JL. Pneumococcal vaccine for infants, toddlers licensed: pricing poses dilemma for CDC committee. Am J Health Syst Pharm 2000;57(7): 625
- Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283(11): 1460–8
- Slattery WH, House JW. Complications of otitis media. In: Lalwani AK, Grundfest KM, eds. Pediatric otology and neurotology. Philadelphia: Lippincott-Raven, 1998
- Brookhouser PE, Auslander MC, Meskan ME. The pattern and stability of postmeningitic hearing loss in children. Laryngoscope 1988; 98(9): 940–8
- Centers for Disease Control and Prevention. Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage. Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2001;50(50): 1120–42